Abstract. Sevoflurane is an inhaled anesthetic that is widely used in clinical practice, particularly for pediatric anesthesia. Previous studies have suggested that sevoflurane may induce neurotoxicity in the brains of neonatal mice. In the present study, the possible mechanism of neurodegeneration induced by sevoflurane in the developing brain, and the possibility that memantine treatment is able to reverse this phenomenon, were investigated. On postnatal day 7 (P7) C57BL/6 mice were continuously exposed to 1.5% sevoflurane for 2 h following pre-injection of saline or memantine. Methyl-CpG island binding protein 2 (MeCP2), cAMP response element-binding protein (CREB) and brain-derived neurotrophic factor (BDNF) expression in the hippocampus was measured by western blotting. Exposure to 1.5% sevoflurane resulted in increased MeCP2 phosphorylation in the hippocampus, which was reversed by memantine injection. However, neither CREB phosphorylation nor BDNF expression were significantly altered by sevoflurane treatment. The current study indicated that sevoflurane causes neurotoxicity in the developing brain, and that this may be attributed to increased MeCP2 phosphorylation in the hippocampus. It was also demonstrated that this neurotoxicity can be prevented by the N-methyl-D-aspartate glutamate receptor inhibitor memantine.

Introduction

Sevoflurane is widely used in the clinic, particularly in pediatric anesthesia. However, infants brains are at a stage at which important changes are occurring, including synapse formation and axon and dendrite growth; this renders them strongly susceptible to environmental influences, such as general anesthetics. A number of studies have demonstrated that early exposure to a variety of anesthetics can cause widespread neurodegeneration in the developing brain and persistent learning deficits (1,2). Loepke et al (3) observed that isoflurane led to apoptotic neurodegeneration, and Head et al (4) elucidated the relevant signaling pathways. Satomoto et al (5) demonstrated that exposing neonatal mice to sevoflurane results in learning deficits, in addition to autism-like abnormal social behavior. These studies together demonstrate that sevoflurane is harmful to the developing brain.

Methyl-CpG island binding protein 2 (MeCP2) is a transcriptional repressor and is important in neuron maturation and normal brain function (6). Studies have suggested that MeCP2 is closely associated with NMDA receptors in the brain (7,8). MeCP2 is a nuclear protein that selectively binds methylated DNA, then recruits other proteins to form an inhibition complex, thereby inhibiting the expression of various genes (9,10). MeCP2 gene mutations can cause the neurodevelopmental disorder Rett syndrome (11), which can lead to cognitive impairment, motor disability and repetitive stereotyped hand movements. Up to 80% of those affected with Rett syndrome experience seizures. A number of studies have hypothesized that these symptoms may be due to defects in experience-dependent synapse maturation (12,13), where normal synapse connections fail to establish in the critical period. These studies have demonstrated that MeCP2 is critical in the maturation of the nervous system and the normal functioning of nerve cells.

cAMP response element-binding protein (CREB) is a nuclear regulatory factor that may regulate gene transcription following phosphorylation of serine 133, thus enhancing the expression of multiple target genes. One study indicated that CREB is the major transcription regulatory factor of brain-derived neurotrophic factor (BDNF), and thus increases BDNF expression. This is a crucial process in the survival and differentiation of neurons (14). Another study demonstrated that isoflurane anesthesia induces neuronal apoptosis by affecting the formation of neuronal synapses in the developmental stages, potentially via the BDNF-p75-RhoA signaling pathway (4).

Memantine is a derivative of amantadine, and acts on the glutamatergic system by inhibiting NMDA receptors. It is involved in neuroprotection and acts to preserve normal synaptic function. It is approved for use in moderate-to-severe Alzheimer's disease, by the FDA and the European Medicines Agency, and has been demonstrated to produce positive effects on cognition, mood and behavior (15,16).
To investigate the molecular mechanism of neurodegeneration induced by sevoflurane, neonatal mice were exposed to sevoflurane and the protein expression levels of CREB and BDNF were assessed in the developing hippocampus. Protein expression levels of MeCP2 and the effect of pre-injected memantine were also examined, in order to determine whether memantine is able to reverse the neurodegeneration.

Materials and methods

Animals and sevoflurane exposure. All animal experiments were performed using protocols approved by the institutional animal use and care committee of the Zhongshan Hospital, Fudan University (Shanghai, China). At postnatal day 7 (P7), male C57BL/6 mice (weight, 3-5 g; Shanghai Laboratory Animal Center, Shanghai, China) were randomly divided into a sevoflurane-treated group (n=6) and an air-treated control group (n=6) for analysis of the effects of sevoflurane on CREB phosphorylation, BDNF expression and MeCP2 phosphorylation levels. Mice were placed in a plastic container and continuously exposed to 1.5% sevoflurane (Maruiushi Pharmaceutical Co., Osaka, Japan) in air, or to air alone for 2 h, with a gas flow of 2 l/min. For further experiments, male C57BL/6 mice at postnatal day 7 (P7) were randomly divided into four groups: The sevoflurane-saline group (sevo group, n=7); the air-saline group (control group, n=6); the sevoflurane-memantine group (sevo+mem group, n=7); and the air-memantine group (mem group, n=6). Mice received 1 mg/kg saline or memantine intraperitoneally prior to sevoflurane or air treatment. The mice were then placed in a plastic container and continuously exposed to 1.5% sevoflurane in air or to air alone for 2 h, with a gas flow of 2 l/min. During exposure to sevoflurane or air, the container was heated to 37°C with a heating pad. The concentrations of sevoflurane, oxygen and carbon dioxide in the container were monitored with a gas monitor (Datex Cardiocab II, Datex-Ohmeda, Madison, WI, USA). Following exposure to sevoflurane or air, the mice were returned to their cages. The mice were housed six per cage and maintained on a 12 h light/dark cycle with access to food and water ad libitum. Two hours post-exposure the mice were sacrificed by decapitation, and their hippocampi were removed.

Arterial blood gas analyses. Arterial blood samples were obtained from the left cardiac ventricle of the mice immediately after exposure to sevoflurane, and were transferred to heparinized glass capillary tubes. Blood pH, partial pressure of carbon dioxide in mmHg (PaCO₂), partial pressure of oxygen in mmHg (PaO₂), lactate (Lac), and bicarbonate (HCO₃⁻) were analyzed immediately after blood collection using a GEM Premier 3000 analyzer (Instrumentation Laboratory, Lexington, MA, USA).

Protein extraction and western blot analysis. Resected hippocampi were placed into 1.5-ml centrifuge tubes and preserved in liquid nitrogen. All methods were conducted on ice. An NE-PER Nuclear and Cytoplasmic Extraction kit (cat no.78835; Thermo Fisher Scientific, Waltham, MA, USA) was used to extract protein samples. All steps were conducted according to the manufacturer's instructions. Sodium dodecyl sulphate (SDS) was added to the samples prior to boiling for 10 min at 100°C. Equal quantities of protein (15 µg) were used to detect the expression of the proteins of interest. Samples were electrophoresed on 10 or 15% SDS polyacrylamide gel, blotted onto polyvinylidene fluoride membranes (Bio-Rad Laboratories, Hercules, CA, USA) and then incubated with the following antibodies overnight at 4°C: Anti-phospho-CREB (ser133), (cat no. 06-519, EMD Millipore, Billerica, MA, USA) 1:4,000 dilution in 5% non-fat milk; anti-CREB (cat no. MAB5432, Millipore) 1:5,000 dilution in 5% non-fat milk; anti-BDNF (cat no. AB1779SP, Millipore) 1:1,000 dilution in 5% non-fat milk; anti-MeCP2 (cat no. 3456P, Cell Signaling Technology, Danvers, MA, USA) 1:4,000 dilution in 5% non-fat milk; anti-phospho-MeCP2-S421 (cat no. AP3693a, Abgent Biotech, Suzhou, China) 1:2,000 dilution in 5% non-fat milk); and anti-actin (cat no. A5441, Sigma-Aldrich, St. Louis, MO, USA) 1:10,000 dilution in 5% non-fat milk. The following day, the blots were incubated for 1 h at room temperature with horseradish peroxidase-conjugated secondary goat anti-rabbit or goat anti-mouse immunoglobulin G (Kangchen, Shanghai, China), 1:5,000 dilution in 5% non-fat milk. Immunoreactive bands were visualized using Amersham ECL Prime Western Blotting Detection kit (cat NO.RPN2232; GE Healthcare, Chalfont St. Giles, UK). The protein signals were quantified using Quantity One software and a GS-800 Calibrated Imaging Densitometer (Bio-Rad Laboratories) and normalized to a corresponding internal reference: CREB for the expression of p-CREB-S133, MeCP2 for P-MeCP2-S421 and actin for BDNF.

Statistical analysis. All data are presented as the mean ± standard error. Data were analyzed using the unpaired Student's t-test in Origin software, version 7.5 (OriginLab, Northampton, MA, USA). P<0.05 was considered to represent a statistically significant difference.

Results

Sevoflurane does not induce metabolic or respiratory deterioration. Blood gas analyses indicated that there was no deterioration in respiration or metabolism in the animals following a 2-h sevoflurane exposure. All parameters were tested, including PH, PaCO₂, PaO₂, oxygen saturation, Lac and HCO₃⁻. No significant differences in any of the parameters were detected between the sevoflurane and the control group (P>0.05; Table I).

Sevoflurane does not cause changes in CREB phosphorylation and BDNF expression in the hippocampus. Western blot analyses of hippocampal CREB phosphorylation and BDNF expression levels were performed 2 h following exposure to sevoflurane or air. The results indicated that there were no significant differences in levels of CREB phosphorylation (Fig. 1) and BDNF (Fig. 2) expression between the sevoflurane-treated (n=6) and air-treated (n=6) groups.

Sevoflurane treatment increases MeCP2 phosphorylation at the serine 421 loci in the hippocampus. Western blot analyses of hippocampal MeCP2 phosphorylation in the
Sevoflurane-treated and control groups were performed 2 h following exposure to sevoflurane or air. The results indicated that sevoflurane-treated mice exhibited an increase in hippocampal MeCP2 phosphorylation at serine 421 loci (P-MeCP2-S421), compared with phosphorylation in the hippocampi of the control mice. The expression level of P-MeCP2-S421 was increased in the sevoflurane-treated group (n=6) compared with the control group (n=6) (P<0.05; Fig. 3).

Sevoflurane increases the MeCP2 phosphorylation at the serine 421 loci in the hippocampus, and pre-injection of memantine reverses this phenomenon. Western blot analyses of hippocampal MeCP2 phosphorylation were performed 2 h following exposure to sevoflurane or air. Compared with the control group (air and saline, n=6), the sevo group (sevoflurane)

Table I. Arterial blood gas analysis.

<table>
<thead>
<tr>
<th>Arterial blood gas</th>
<th>Control (n=6)</th>
<th>Sevoflurane (n=6)</th>
</tr>
</thead>
<tbody>
<tr>
<td>pH</td>
<td>7.4±0.05</td>
<td>7.38±0.04</td>
</tr>
<tr>
<td>PaCO₂ (mmHg)</td>
<td>28.4±3.0</td>
<td>30.1±4.0</td>
</tr>
<tr>
<td>PaO₂ (mmHg)</td>
<td>91.0±6.8</td>
<td>88.8±5.6</td>
</tr>
<tr>
<td>SaO₂ (%)</td>
<td>93.6±2.6</td>
<td>92.7±2.5</td>
</tr>
<tr>
<td>Lac (mmol/l)</td>
<td>1.1±0.5</td>
<td>1.2±0.4</td>
</tr>
<tr>
<td>HCO₃ (mmol/l)</td>
<td>23.8±1.6</td>
<td>24.1±1.5</td>
</tr>
</tbody>
</table>

Exposure to sevoflurane did not induce significant metabolic or respiratory impairment. Analysis of arterial blood gas revealed no significant differences in any of the measured parameters between the sevoflurane group and the control one (t-test, P>0.05). Pa, partial pressure; Sa, saturation.
and saline, n=7) exhibited a significant increase in hippocampal P-MeCP2-S421 expression levels (P<0.05; Fig. 4). Compared with the sevo group, the sevo+mem group exhibited a significant decrease in hippocampal P-MeCP2-S421 levels (P<0.05; Fig. 4). No significant difference was detected between the mem group (memantine and saline, n=6) and the control group (n=6).

Discussion

In the present study, it was demonstrated that P-MeCP2-S421 expression levels in hippocampi resected at P7 increased in mice exposed to 1.5% sevoflurane for 2 h, and that memantine pre-injection was able to reverse this increase. However, sevoflurane did not cause significant changes in CREB phosphorylation and BDNF expression levels in the hippocampus.

A dose of 1.5% sevoflurane, which did not inhibit respiration and circulation in mouse pups, was selected for the current study. Arterial blood analyses confirmed that none of the mice experienced hypoxemia or hypercapnia during the 2-h sevoflurane exposure; there were no significant differences in any of the tested parameters between the sevoflurane group and the control group. These results exclude the possibility of hypoxemia and hypercapnia affecting the outcome of the following experiments.

A previous study demonstrated that early exposure to sevoflurane causes widespread neurodegeneration in the developing brain (17). However, the exact mechanism of action underlying the effect of sevoflurane remains unknown. The results of the present study may provide a possible explanation for sevoflurane-mediated neurodegeneration, as they suggested that MeCP2 may be important in neuronal degeneration following neonatal sevoflurane exposure.

The γ-aminobutyric acid type A (GABA) and N-methyl-D-aspartate glutamate (NMDA) receptors are essential for the development of an ordered neural map (18,19), and are important in the alteration of synaptic transmission. Neurotransmitters or compounds that act on them may contribute to the impairment of brain development and synaptogenesis (20,21). MeCP2 links closely with NMDA receptors in the brain, and NMDA receptors (particularly NR2A) are essential for visual cortical function in the absence of MeCP2 (22). The activity-dependent expression of another NMDA subunit (NR2B) is mediated by MeCP2-dependent epigenetic regulation (23). Thus, as indicated in the present study, MeCP2 may regulate NMDA receptors, leading to various effects on brain function in mice. MeCP2 phosphorylation at serine 421 loci is a key signal, which may cause downstream changes in the signaling pathway and influence the central nervous system. Previous studies indicated that CDKL5 is a target of MeCP2 in the brain, and is regulated by DNA methylation (24). MeCP2 can also interact with some microRNAs to regulate brain function (25). Further study of these aspects is required in order to figure out whether and how microRNAs are involved in the regulation of neuroplasticity in the brain.

Memantine is an amantadine derivative and NMDA receptor inhibitor. It has been used to treat Alzheimer’s disease and is accepted to be safer than other NMDA receptor inhibitors, as a therapeutic dose of memantine has a greater affinity for synaptic NMDA receptors than extrasynaptic NMDA receptors. Thus, it exhibits an important role in neuroprotection, while preserving normal synaptic function (26). In the present study, memantine was able to reverse the increase in MeCP2 phosphorylation in the hippocampus following sevoflurane exposure. This demonstrates that memantine may have a protective effect against neurodegeneration induced by sevoflurane exposure.

In conclusion, the results of the present study demonstrated that P-MeCP2-S421 expression levels in the hippocampus increased in P7 mice exposed to 1.5% sevoflurane for 2 h, and pre-injected memantine reversed this increase. Sevoflurane did not cause changes in CREB phosphorylation or BDNF expression levels in the hippocampus. Future investigation of MeCP2 and NMDA receptors is required in order to further investigate their effects on the central nervous system during its development.

Acknowledgements

The current study was supported by grants from the National Natural Science Foundation of China (grant no. 81100796).

References

14. Tao X, Finkbeiner S, Arnold DB, Shaywitz AJ and Greenberg ME: 